Kao, M.-W.; Kuo, Y.-H.; Hsieh, K.-C.; Lee, C.-T.; Wu, S.-C.; Yang, W.-C.
Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. Int. J. Mol. Sci. 2023, 24, 7312.
https://doi.org/10.3390/ijms24087312
AMA Style
Kao M-W, Kuo Y-H, Hsieh K-C, Lee C-T, Wu S-C, Yang W-C.
Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. International Journal of Molecular Sciences. 2023; 24(8):7312.
https://doi.org/10.3390/ijms24087312
Chicago/Turabian Style
Kao, Ming-Wei, Yao-Hung Kuo, Kun-Chou Hsieh, Ching-Tai Lee, Shih-Chi Wu, and Wen-Chi Yang.
2023. "Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience" International Journal of Molecular Sciences 24, no. 8: 7312.
https://doi.org/10.3390/ijms24087312
APA Style
Kao, M.-W., Kuo, Y.-H., Hsieh, K.-C., Lee, C.-T., Wu, S.-C., & Yang, W.-C.
(2023). Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience. International Journal of Molecular Sciences, 24(8), 7312.
https://doi.org/10.3390/ijms24087312